Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.
|Slideshows|October 23, 2019
When Eating Disorders and Psychosis Co-Exist: 6 Take Home Points
Author(s)Mary V. Seeman, MDCM, DSc
The body image disturbance at the heart of anorexia nervosa is a false perception akin to the perceptual disorders found in schizophrenia.
Advertisement
Advertisement
Related to this article
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
A Delphi panel recommends screening for eating disorders before GLP-1 receptor agonist initiation.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
3
Schizophrenia: A Telltale of the Brain’s Complexity
4
Podcast: Interventional Psychiatry and the Challenge of Difficult-to-Treat Depression
5